Adalimumab treatment of resistant chondrocalcinosis

Tastekin, Fatih; Aksu, Kenan

doi:10.1016/j.reumae.2024.09.007

array:23 ["pii" => "S2173574324001163" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.007" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1777" "copyright" => "Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U." "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2024;20:452-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S2173574324001102" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.001" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1774" "copyright" => "Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2024;20:454-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Letter to the Editor in response to: “Spontaneous pneumomediastinum: An extra muscular manifestation of anti-MDA5 dermatomyositis. Report of 2 cases”" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "454" "paginaFinal" => "455" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Carta al editor en respuesta a: «Neumomediastino espontáneo: una manifestación extramuscular de la dermatomiositis anti-MDA5. Reporte de 2 casos»" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1441 "Ancho" => 2216 "Tamanyo" => 225028 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Proposed classification of pneumomediastinum. * Precipitating factors can act upon predisposing factors." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Santiago Campbell-Silva, Iyuleisa Castro-González, Santiago Campbell-Quintero, Sebastián Campbell-Quintero" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Santiago" "apellidos" => "Campbell-Silva" ] 1 => array:2 [ "nombre" => "Iyuleisa" "apellidos" => "Castro-González" ] 2 => array:2 [ "nombre" => "Santiago" "apellidos" => "Campbell-Quintero" ] 3 => array:2 [ "nombre" => "Sebastián" "apellidos" => "Campbell-Quintero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X24000688" "doi" => "10.1016/j.reuma.2024.05.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X24000688?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324001102?idApp=UINPBA00004M" "url" => "/21735743/0000002000000008/v1_202410110607/S2173574324001102/v1_202410110607/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2173574324001151" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.006" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1782" "copyright" => "The Author(s)" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Reumatol Clin. 2024;20:440-51" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Efficacy of psychological interventions to reduce anxiety and depression in patients with lupus. A systematic review and meta-analysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "440" "paginaFinal" => "451" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eficacia de las intervenciones psicológicas para reducir la ansiedad y depresión en pacientes con lupus. Una revisión sistemática y metaanálisis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1825 "Ancho" => 3592 "Tamanyo" => 465918 ] ] "descripcion" => array:1 [ "en" => "PRISMA 2020 flow diagram." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jose Luis Vicente-Escudero" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Jose Luis" "apellidos" => "Vicente-Escudero" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324001151?idApp=UINPBA00004M" "url" => "/21735743/0000002000000008/v1_202410110607/S2173574324001151/v1_202410110607/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "Case report" "titulo" => "Adalimumab treatment of resistant chondrocalcinosis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "452" "paginaFinal" => "453" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Fatih Tastekin, Kenan Aksu" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Fatih" "apellidos" => "Tastekin" "email" => array:1 [ 0 => "fatihtastekin@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Kenan" "apellidos" => "Aksu" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Ege University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento con adalimumab de la condrocalcinosis resistente" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 948 "Ancho" => 975 "Tamanyo" => 53824 ] ] "descripcion" => array:1 [ "en" => "CPPD on the patient's direct radiograph." ] ] ] "textoCompleto" => "IntroductionCalcium pyrophosphate dihydrate deposition (CPPD) is an inflammatory disease caused by the deposition of calcium pyrophosphate crystals in the joints. Although CPPD can stay mostly asymptomatic, it can present as acute or chronic arthritis.<a class="elsevierStyleCrossRefs" href="#bib0055">1,2</a> Intra-articular corticosteroids injection, non-steroidal anti-inflammatory drugs, colchicine, methotrexate and hydroxychloroquine can be used for CPPD. In resistant cases, biological treatments can also be used. IL-1 inhibitor anakinra is the most widely used biological agent for chondrocalcinosis.<a class="elsevierStyleCrossRefs" href="#bib0065">3–5</a> Since TNF is also involved in the pathophysiology, anti-TNF drugs are also considered to be used in treatment.Case presentationForty-six years old male patient presented with history of hip and joint pain for 2 years. His pains were resistant to analgesics. He does not have any comorbidities. He does not have any family history of CPPD or CPPD like symptoms. On laboratory examination C-reactive protein was 2.35mg/L (0–5), serum calcium was 9.2mg/dL (8.6–10.2), magnesium was 1.81mg/dL (1.5–2.6), uric acid was 4.1mg/dL (3.5–7.2), ferritin was 23.5μg/L (30–400), erythrocyte sedimentation rate was 2mm/h (<15), parathormone was 56.82ng/L (15–65), thyroid releasing hormone was: 0.953mU/L (0.27–4.2) and vitamin D was 48ng/mL (20–50). Rheumatoid factor and antinuclear antibodies were negative. HLA-B27, HLA B-51, HLA B52 were negative. There was no history of inflammatory bowel disease and psoriasis. X-rays revealed chondrocalcinosis of the glenohumoral joints, intervertebral disks, acetabular joints, iliac crests, femoral trochanters, iliopubic tuberosities, symphisis pubis, meniscuses, knee joint cartilages, ankles, tarsal joints and heels (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). In his magnetic resonance imagining chondrocalcinosis and early coxarthrosis was seen in bilateral hip joints. There was not any sign of sacroiliac inflammation. He was refractory to multiple NSAIDs, colchicine, sulfasalazine, methotrexate and low-middle dose corticosteroid. Subcutaneous adalimumab 40mg was started each 2 weeks. Methotrexate and 2mg dexamethasone treatments continued. A major reduction of pain was observed in his 3 months follow-up. No side effects of adalimumab were observed. The patient's follow-up continues stably under anti-TNF therapy.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>DiscussionIn the literature, successfully treated cases with IL-1R antagonist anakinra are published.<a class="elsevierStyleCrossRefs" href="#bib0070">4–6</a> One of the cases treated with anakinra was resistant to adalimumab treatment.<a class="elsevierStyleCrossRef" href="#bib0070">4</a> Patients that successfully managed with the IL-6 receptor inhibitor tocilizumab that resistant to anakinra was also reported.<a class="elsevierStyleCrossRefs" href="#bib0085">7,8</a> In a report infliximab was used for treatment of two resistant chondrocalcinosis and results has been shown to be effective.<a class="elsevierStyleCrossRef" href="#bib0095">9</a> Although several reports exist of monosodium urate crystals deposition being successfully treated with anti-TNFα drugs, published cases of CPPD successfully treated with these agents are lacking.<a class="elsevierStyleCrossRef" href="#bib0100">10</a> Due to various roles of TNF in inflammatory processes we decided to use anti-TNF blocking agent adalimumab in therapy of resistant chondrocalcinosis patient. In the follow-up periods the patient had really good answer to our therapy and there were no major side effects. To our knowledge, this is the first report using adalimumab successfully in severe CPDD.FundingThis research received no financial support from any funding agency in the public, commercial, or not-for-profit sectors.Informed consentInformed consent was taken from patient.Conflict of interestsAll other authors declare no competing interests." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres2269788" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1892471" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2269787" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1892470" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Case presentation" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Funding" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Informed consent" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflict of interests" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-05-02" "fechaAceptado" => "2024-06-21" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1892471" "palabras" => array:4 [ 0 => "Calcium pyrophosphate" 1 => "Chondrocalcinosis" 2 => "Tumor necrosis factor-alpha" 3 => "Adalimumab" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1892470" "palabras" => array:4 [ 0 => "Pirofosfato cálcico" 1 => "Condrocalcinosis" 2 => "Factor de necrosis tumoral alfa" 3 => "Adalimumab" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "In this article, we present a case of resistant chondrocalcinosis who had a good response with 40mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "En este artículo, presentamos un caso de condrocalcinosis resistente que tuvo una buena respuesta con 40mg de adalimumab subcutáneo. Hasta donde sabemos, este es el primer informe en el que se utiliza adalimumab con éxito en la enfermedad por depósitos de cristales de pirofosfato de calcio dihidratado (CPPD) grave. El tratamiento anti-TNF puede ser una buena opción terapéutica de segunda línea en la CPPD." ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 948 "Ancho" => 975 "Tamanyo" => 53824 ] ] "descripcion" => array:1 [ "en" => "CPPD on the patient's direct radiograph." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cartilage diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Krishnan" 1 => "A.J. Grodzinsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.matbio.2018.05.005" "Revista" => array:5 [ "tituloSerie" => "Matrix Biol" "fecha" => "2018" "volumen" => "71–72" "paginaInicial" => "51" "paginaFinal" => "69" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcium pyrophosphate deposition disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.K. Rosenthal" 1 => "L.M. Ryan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra1511117" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2016" "volumen" => "374" "paginaInicial" => "2575" "paginaFinal" => "2584" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27355536" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563-70, https://doi.org/10.1136/ard.2010.139105 [Epub 7.01.2011; PMID: 21216817]." ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E. Cipolletta" 1 => "A. DI Matteo" 2 => "A. Scanu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2020" "volumen" => "38" "paginaInicial" => "1001" "paginaFinal" => "1007" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32359034" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcium pyrophosphate deposition (CPPD) disease – treatment options" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Stack" 1 => "G. Mccarthy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.berh.2021.101720" "Revista" => array:5 [ "tituloSerie" => "Best Pract Res Clin Rheumatol" "fecha" => "2021" "volumen" => "35" "paginaInicial" => "101720" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34756508" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Thomas" 1 => "M. Forien" 2 => "E. Palazzo" 3 => "P. Dieudé" 4 => "S. Ottaviani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-018-4272-2" "Revista" => array:5 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2019" "volumen" => "38" "paginaInicial" => "425" "paginaFinal" => "430" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "N. Quilis" 1 => "M. Andrés" 2 => "P. Vela" 3 => "E. Pascual" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jbspin.2017.04.008" "Revista" => array:5 [ "tituloSerie" => "Joint Bone Spine" "fecha" => "2018" "volumen" => "85" "paginaInicial" => "377" "paginaFinal" => "378" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Latourte" 1 => "H.K. EA" 2 => "A. Frazier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2020-217188" "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2020" "volumen" => "79" "paginaInicial" => "1126" "paginaFinal" => "1128" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Bruges-Armas" 1 => "B.F. Bettencourt" 2 => "A.R. Couto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2014/536856" "Revista" => array:4 [ "tituloSerie" => "Case Rep Rheumatol" "fecha" => "2014" "volumen" => "2014" "paginaInicial" => "536856" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The emerging role of biotechnological drugs in the treatment of gout" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Cavagna" 1 => "W.J. Taylor" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2014/264859" "Revista" => array:5 [ "tituloSerie" => "Biomed Res Int" "fecha" => "2014" "volumen" => "2014" "paginaInicial" => "264859" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24839602" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000002000000008/v1_202410110607/S2173574324001163/v1_202410110607/en/main.assets" "Apartado" => array:4 [ "identificador" => "43296" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case report" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000002000000008/v1_202410110607/S2173574324001163/v1_202410110607/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324001163?idApp=UINPBA00004M"]

Reumatología Clínica (English Edition)

ISSN: 2173-5743

Reumatología Clínica is the official publication of scientific Spanish Society of Rheumatology (SER) and the Mexican College of Rheumatology (CMR). Reumatología Clínica publishes original research papers, editorials, reviews, case reports and pictures. Published studies are primarily clinical and epidemiological research but also basic.

Indexed in:

Web of Science, Index Medicus/MEDLINE, Scopus, ESCI (Emerging Sources Citation Index), IBECS, IME, CINAHL

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.2

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

2.4

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.31

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.431

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 20. Issue 8.

Pages 452-453 (October 2024)

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)

Member of the society

Subscriber

Contact

Member

If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Reumatología Clínica (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

atencionalcliente@elsevier.com

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter